URL has been copied successfully!
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We have some news out of Washington, and a look at a company flush with cash. Let’s get to it.
The need-to-know this morning
- Abivax disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks.
FDA’s top gene therapy regulator steps down
Vijay Kumar is leaving his role as acting director of the office that reviews cell and gene therapies at the FDA, according to an email obtained by STAT.
Please follow us:
